Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital, SE-171 76 Stockholm, Sweden.
J Transl Med. 2013 Oct 6;11:247. doi: 10.1186/1479-5876-11-247.
HLA abnormalities on tumour cells for immune escape have been widely described. In addition, cellular components of the tumour microenvironment, in particular myeloid derived suppressor cells (MDSC) and alternatively activated M2 tumour-associated macrophages (TAMs), are involved in tumour promotion, progression, angiogenesis and suppression of anti-tumour immunity. However, the role of HLA in these activities is poorly understood. This review details MHC class I characteristics and describes MHC class I receptors functions. This analysis established the basis for a reflection about the crosstalk among the tumour cells, the TAMs and the cells mediating an immune response.The tumour cells and TAMs exploit MHC class I molecules to modulate the surrounding immune cells. HLA A, B, C and G molecules down-regulate the macrophage myeloid activation through the interaction with the inhibitory LILRB receptors. HLA A, B, C are able to engage inhibitory KIR receptors negatively regulating the Natural Killer and cytotoxic T lymphocytes function while HLA-G induces the secretion of pro-angiogenic cytokines and chemokine thanks to an activator KIR receptor expressed by a minority of peripheral NK cells. The open conformer of classical MHC-I is able to interact with LILRA receptors described as being associated to the Th2-type cytokine response, triggering a condition for the M2 like TAM polarization. In addition, HLA-E antigens on the surface of the TAMs bind the inhibitory receptor CD94/NKG2A expressed by a subset of NK cells and activated cytotoxic T lymphocytes protecting from the cytolysis.Furthermore MHC class II expression by antigen presenting cells is finely regulated by factors provided with immunological capacities. Tumour-associated macrophages show an epigenetically controlled down-regulation of the MHC class II expression induced by the decoy receptor DcR3, a member of the TNFR, which further enhances the M2-like polarization. BAT3, a positive regulator of MHC class II expression in normal macrophages, seems to be secreted by TAMs, consequently lacking its intracellular function, it looks like acting as an immunosuppressive factor.In conclusion HLA could cover a considerable role in tumour-development orchestrated by tumour-associated macrophages.
肿瘤细胞上的 HLA 异常可导致免疫逃逸,这一现象已得到广泛描述。此外,肿瘤微环境中的细胞成分,特别是髓系来源的抑制性细胞(MDSC)和替代性激活的 M2 肿瘤相关巨噬细胞(TAMs),参与肿瘤的促进、进展、血管生成和抑制抗肿瘤免疫。然而,HLA 在这些活动中的作用尚不清楚。本文详细描述了 MHC Ⅰ类分子的特征,并描述了 MHC Ⅰ类受体的功能。该分析为探讨肿瘤细胞、TAMs 和介导免疫反应的细胞之间的串扰奠定了基础。肿瘤细胞和 TAMs 利用 MHC Ⅰ类分子来调节周围的免疫细胞。HLA A、B、C 和 G 分子通过与抑制性 LILRB 受体相互作用下调巨噬细胞的髓样激活。HLA A、B、C 能够与负调节自然杀伤细胞和细胞毒性 T 淋巴细胞功能的抑制性 KIR 受体结合,而 HLA-G 通过少数外周 NK 细胞表达的激活性 KIR 受体诱导促血管生成细胞因子和趋化因子的分泌。经典 MHC-I 的开放构象能够与描述为与 Th2 型细胞因子反应相关的 LILRA 受体相互作用,触发 M2 样 TAM 极化的条件。此外,TAMs 表面的 HLA-E 抗原与 NK 细胞和活化的细胞毒性 T 淋巴细胞表达的抑制性受体 CD94/NKG2A 结合,防止细胞溶解。此外,抗原呈递细胞的 MHC Ⅱ类表达受到具有免疫能力的因子的精细调节。肿瘤相关巨噬细胞表现出由 TNFR 成员诱饵受体 DcR3 诱导的 MHC Ⅱ类表达的表观遗传下调,进一步增强了 M2 样极化。BAT3 是正常巨噬细胞中 MHC Ⅱ类表达的正调节剂,似乎由 TAMs 分泌,因此缺乏其细胞内功能,它似乎作为一种免疫抑制因子发挥作用。总之,HLA 在肿瘤相关巨噬细胞介导的肿瘤发生中可能发挥重要作用。